Roth Capital maintains $25 price target on BioAge Labs
Roth Capital maintained its price target of $25.00 per share for BioAge Labs, according to Benzinga’s ratings actions.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.